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Sununa"r Twenty-nine patients with adenocarcinomas of gastrointestinal or unknown primarv, and three
with advanced neuroendocrine tumours, were entered into a study of bolus plus infusional S-fluorouracil
(FUra) modulated with high-dose leucovorin (LV) and recombinant interferon .2a (IFN-a). Successive cohorts
of > 4 patients received IFN-a at 1.5. 3, 4.5. 6 and 9 MU on alternate days throughout the treatment period.
The FUra LV regimen consisted of: LV 200 mg m i.v. infusion over 2 h. FUra 400 mg m' i.v. bolus then
FUra 400 mg m-' i.v. infusion over 22 h, all repeated on day 2, on a 14-day cycle. FUra was given at 75%
dose for the first course. increasing (in the absence of WHO grade > 2 toxicity) to 87.5% for the second and
100% for subsequent courses up to a maximum of 12. The maximum tolerated dose (MTD) of IFN-a was
6 MU on alternate days. with 7 8 patients at 9 MU requiring dose reductions. At 6 MU IFN-a. the MTD of
FUra was not exceeded at 100% (i.e. 400mg m2 bolus and infusion. days 1 and 2). and FUra-related
toxicities (mucosal, haematological, dermatological) were extremely mild. Twenty-nine patients were assessable
for tumour response, among whom WHO criteria partial responses were seen in 7 14 with colorectal. 1 4 with
gastric. 0 1 with pancreatic. 1 3 with neuroendocrine and 3'6 with unknown primaries. Median response
duration was 51 weeks. Minor responses and stable disease were seen in a further six patients. Median survival
of patients with advanced adenocarcinomas was 9 months, with 33% surviving beyond 18 months. This
schedule offers a safe way of co-administering FUra. LV and IFN-a. The addition of IFN-z. while causing
significant independent toxicity, does not significantly increase the dose-limiting mucosal toxicities of FUra
LV. Further investigation is required to determine the contribution of IFN-a to the anti-tumour activity of the
combination.
Thirty-six years after its development. 5-fluorouracil (FUra)
remains the single most successful cytotoxic drug for the
treatment of gastrointestinal cancers and an important com-
ponent of combination chemotherapy for carcinomas of
several other sites. However, this lofty status belies a degree
of objective activity which is, at best. modest: in advanced
colorectal cancer, single-agent bolus FUra schedules give
objective response rates of less than 10% (ACCMP, 1992). In
the absence of superior cytotoxic agents, attention has
focused on improving the activity of FUra, either by chang-
ing its administration schedule (pharmacodynamic modula-
tion) or by exploiting interactions with other agents
(biochemical modulation).
FUra exerts its cytotoxicity through a combination of
mechanisms, including (1) inhibition of thymidylate synthase
(TS) by 5-fluorodeoxyuridine monophosphate (FdUMP),
with consequent depletion of thymidylate. (2) misincorpora-
tion into DNA of the deoxyuridine bases deoxyuridine tri-
phosphate (dUTP) and 5-fluorodeoxyuridine triphosphate
(FdUTP) and (3) misincorporation into RNA of 5-fluoro-
uridine triphosphate (FUTP). Modulation strategies may
alter the relative contributions of these cytotoxic mechanisms
in a way which improves FUra's therapeutic index.
Many different biochemical modulators of FUra have been
investigated. of which the best established is leucovorin (LV).
This supplements reduced folate pools. including 5.10-methyl-
enetetrahydrofolate polyglutamate. the co-factor required for
stabilisation of a ternary complex of FdUMP with TS. In
high weekly doses (Petrelli et al.. 1989) and in lower daily
repeated doses (Poon et al.. 1991). LV has been shown to
improve the clinical activity of FUra. As an alternative or
adjunct to biochemical modulation. FUra's activity may be
modulated by its administration schedule, since infusional
administration may favour its phase-specific. DNA-directed
mechanisms. Short. intermittent infusions lasting 24-72 h
(Shah et al.. 1985) or uninterrupted ambulatory infusions
(Lokich et al.. 1989) of single-agent FUra produce higher
objective response rates than do bolus schedules, although
the experience with medium-term (5-14 days) intermittent
infusion has been mixed (Kemeny et al.. 1990: Weinerman et
al.. 1992).
There are numerous laboratory reports of synergistic
interactions between interferons (IFNs) and cytotoxic drugs
(comprehensively reviewed by Wadler & Schwartz. 1990). Of
these, the interaction with FUra has been most extensively
studied; it is IFN dose dependent and is abrogated by the
addition of thymidine, pointing to the TS,DNA (rather than
the FUTP/RNA) axis of FUra cytotoxicity (Elias & Criss-
man, 1988). Observations in tumour cell lines treated with
interferons a or 7 include:
increased activity of thymidine phosphorylase. which con-
verts FUra to fluorodeoxyuridine, leading to accumula-
tion of FdUMP (Elias & Sandoval. 1989; Schwartz et al.,
1992);
failure to up-regulate the expression or activity of TS in
response to its inhibition (Chu et al.. 1990: Seymour et al..
1992a);
* an increase in FUra-induced double-stranded DNA
breaks (Houghton et al.. 1993).
Further mechanisms may operate in vivo. including reduc-
ed activity of the FUra catabolising enzyme, dihydro-
pyrimidine dehydrogenase (DPD) (Yee et al.. 1992) and
delayed clearance of FUra from tumour tissues (Seymour et
al., 1992b). Conversely. FUra may potentiate IFN-stimulated
cellular cytotoxicity (Neefe & Glass, 1991).
It might be predicted that the modulations of FUra by
IFN and by LV are complementary. IFN appears to favour
the generation of the TS inhibitor. FdUMP. and to inhibit
adaptive up-regulation of the target enzyme, while LV
supplements the pool of reduced folate required as a co-
factor for maintenance of the TS-FdUMP ternary complex.
When used in vitro at clinically achievable concentrations, the
two modulators together produce greater enhancement of
FUra toxicity against two human colorectal carcinoma cell
lines than either alone (Houghton et al.. 1991).
This phase I and II study was therefore undertaken to
establish a safe and tolerable regimen for the co-admin-
istration of FUra. LV and IFN-mc. and to give an indication
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of its activity in a population of patients with advanced
gastrointestinal adenocarcinomas. The baseline regimen
chosen for the study was that of de Gramont et al. (1988),
which includes a moderately high dose of LV together with
both bolus and infusional FUra totalling 48 h treatment,
given on a fortnightly cycle. This regimen has previously
been tested in a group of 70 unselected patients in our
hospital and is notable in that it has a mild toxicity profile
but nonetheless produces objective activity similar to more
toxic standard FUra/LV regimens (Johnson et al., 1991).
Paient and methods
The study employed between-patient escalation of the IFN-x
dose and within-patient titration of the FUra dose. The aims
of the study were (1) to determine the maximum tolerable
dose (MTD) of IFN-a; (2) to determine whether the addition
of IFN-c potentiates the dose-limiting toxicities of FUra/LV
and (3) to estimate the activity of the three-drug combina-
tion, in terms of objective tumour response, in patients with
advanced adenocarcinomas. The protocol was approved by
the Local Research Ethics Committee and patients were
treated only after a full explanation of the nature and pur-
pose of the study and with written consent.
Patients
Thirty-two patients were entered between June 1990 and
March 1991, with pretreatment characteristics as shown in
Table I. Patients were eligible for the study if they had
histologically confirmed adenocarcinoma of the gastrointes-
tinal tract, adenocarcinoma of unknown primary or neuro-
endocrine tumour and had not previously been treated with
chemotherapy. Two patients were treated adjuvantly follow-
ing resection of stage C3 colonic carcinoma. For all others,
the indication for chemotherapy was advanced disease not
amenable to local treatment modalities, and all but one had
measurable disease by CT scan.
Life expectancy of > 3 months and Karnofsky perfor-
mance status of > 60% were required, as were pretreatment
WBC > 3.5 x 109 1-', neutrophils > 2 x 109 1' and platelets
> 150 x 1091-'. Patients with creatinine or EDTA clearance
of <50mlmin'- were excluded because of the likely effect
on IFN-x pharmacokinetics, but hepatic dysfunction was not
an exclusion criterion.
Treatment
Recombinant interferon a2a (IFN-x) was supplied for this
study by Roche Products, UK. To simplify self-admini-
stration, the dose of IFN-a was not adjusted by patient
Table I Patient charactistics (n = 32)
Male female
Median age (range)
Karnofsky performance status
100
80-90
60-70
Primary site
Colonwrectum
Stomach
Pancreas
Unknown
Neuroendocrine
Sites of active disease
Liver
Other pelvis/abdomen
Lungs/mediastinum
Bones bone marrow
Measurable
Advanced but not measurable
Adjuvant
18, 14
51 (31-78)
6
22
4
17
5
6
3
(19%)
(69%)
(13%)
(53%)
(16%)
(3%)
(19%)
(10%)
17 (53%)
19 (60%)
7 (22%)
5 (16%)
29
1
2
surface area. IFN-a was given subcutaneously (s.c.) on alter-
nate evenings throughout the study period. Successive
cohorts of patients were treated at dose levels of 1.5 MU
(four patients), 3 MU (four patients), 4.5 MU (four patients),
6 MU (12 patients) and 9 MU (eight patients). Patients
within each cohort stayed on that dose of IFN-a unless a
dose reduction for toxicity was required. The maximum
tolerated dose (MTD) of IFN-a was predefmed as the highest
dose level tolerated without reduction by at least two-thirds
of patients.
Chemotherapy was given fortnightly using the regimen of
de Gramont (De Gramont et al., 1988; Johnson et al., 1991).
The 'full dose' regimen, determined by these two studies,
consists of: LV 200 mg m-2 (maximum 350 mg) in 500 ml of
saline i.v. over 2 h, then FUra 400mgm2 i.v. bolus, then
FUra 400 mg m-2 i.v. infusion over 22 h, all repeated on day
2. However, because of the possibility that IFN-a may poten-
tiate the toxicity of FUra/LV, the FUra (both bolus and
infusion) was given at 75% dose for the first cycle and
escalated to full dose in two stages. Escalations were made
provided the blood count on the day of treatment showed
WBC > 3.5 x 1091-', neutrophils > 2.0 x IO0 1'- and plate-
lets > 100 x 1091-', and there had been no non-haemato-
logical toxicity of WHO grade > 2 (WHO, 1979).
Treatment was administered in hospital, via a peripheral
venous cannula. Infusion flow rates were controlled using
electrical pumps. Routine antiemetic prophylaxis was not
used. Treatment was given up to a maximum of 12 cycles (6
months) to patients with stable or responding disease.
Thereafter patients were observed, further treatment being
offered upon disease progression as appropriate.
Monitoring andassessment
A clinical history and examination, full blood count and
biochemical profile were performed prior to each treatment
cycle, along with assessment of non-haematological toxicity,
scored using WHO criteria.
Other investigations were performed as clinically indicated.
The sites of measurable disease were reassessed by com-
puterised tomographic (CT) scan after each six cycles of
treatment, and standard WHO criteria were used for the
definition of response to treatment (WHO, 1979). Changes in
carcinoembryonic antigen (CEA) or liver enzymes were used
as a guide to further investigation but not as sole evidence
for disease response. On completing 12 cycles of
chemotherapy, patients were followed up off treatment at 2
monthly intervals until progression, then offered second-line
therapy if appropriate.
Resdks
Thirty-two patients received a total of 244 cycles of chemo-
therapy. Follow-up is now complete, all patients having
relapsed and only three remaining alive.
Maximum tolerateddose (MTD)
Interferon IFN-x dose reductions were required in 0/4
patients treated at the 3 MU IFN-x dose level, 1/4 each at
the 1.5 and 4.5 MU levels, 2/12 at the 6 MU level and 7/8 at
the 9 MU level. Thus the MTD for IFN-x was 6 MU on
alternate days. However, there was marked variability: for
exnample, one patient complained of severe lethargy and
anorexia even at the 1.5 MU level, which resolved only after
stopping IFN-a altogether.
One patient who had bone marrow infiltration developed
persistent neutropenia on 9 MU IFN-x which recovered after
dose reduction. A man with advanced gastric carcinoma,
who also had systemic sclerosis, developed marked deteriora-
tion of the systemic sclerosis while on IFN-a 9 MU, where-
upon it was stopped. All other IFN-x dose reductions were
made for subjective toxicities such as lethargy, malaise or
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FL'ra This study was not designed to redetermine the MTD
for FUra, only to determine whether it is necessary to reduce
the dose of FUra compared with that which is well tolerated
in the absence of IFN-x. In 25 of the 32 patients, the FUra
dose escalation from 75% to 87.5% to 100% levels pro-
ceeded without any delay. When escalation did not proceed
smoothly, the usual cause was mild myelotoxicity. However.
only one patient, who had bone marrow infiltration and was
treated at the 9 MU IFN-a level, developed neutropenia of
<1.0 x 1091-'. Gastrointestinal toxicity was generally mild.
and did not impede FUra dose escalation. Thus the MTD for
FUra in the presence of IFN-a was not exceeded at 400 mg
m bolus +400mgm-2 infusion, day 1+2, and is not
significantly different from the MTD of the same regimen
without IFN-a.
Toxicity
The incidence of toxicity is shown in Figure 1 as a propor-
tion of the number of courses of treatment administered. at
each IFN-a dose level. For comparison are shown the toxi-
cities recorded during a previous phase II study of the same
regimen of FUra/LV, without IFN-a, conducted in the same
institution (Johnson et al., 1991). This historical comparison
suggests a slight increase in all classes of toxicity when IFN-a
is added to the regimen; however, no IFN-a dose relationship
was found for the incidence or degree of myelosuppression.
nausea and vomiting, mucositis or diarrhoea (upper five
histograms, Figure 1). Severe lethargy (WHO grade 3) was
seen in several patients at 9 MU IFN-a, but no dose relation-
ship was found over the range 1.5-6 MU. There were no
instances of grade 4 toxicity or of neutropenia-associated
fever.
Plantar-palmar erythrodysaesthesia ('hand-foot synd-
rome') occurred in 11 patients, usually only after more than 2
months' treatment. Several of these patients also had mild
facial rashes, conjunctivitis and alopecia. Pyridoxine 50 mg
t.d.s. provided partial relief from the dermatological side-
effects. Other toxicities were extremely mild. One patient, at
the 3 MU IFN-a level, developed mild ata.xia during the
FUra infusion and for 24 h afterwards, which recurred dur-
ing the subsequent cycles. No cardiotoxicity was noted.
Anti-tumour responses
No complete responses were seen. Among the 29 assessable
patients, objective partial responses were seen in 7 of the 14
with colorectal cancer, three of the six with adenocarcinoma
of unknown primary site, one of four with gastric carcinoma,
none of one with pancreatic cancer and one of three with
neuroendocrine tumours. All patients have subsequently
relapsed; median response duration was 51 weeks (range
14-98 weeks). Two other patients had radiological responses
not amounting to WHO PR, but accompanied by resolution
of symptoms, signs and tumour markers ('MR'), lasting for
30 and 54 weeks. Three patients had stable disease (SD) for
22, 29 and 44 weeks. Eleven patients had progressive disease
(PD) on treatment. The breakdown of response by IFN-a
level is given in Table II: responses occurred at all IFN-a
dose levels.
Survival
After exclusion of patients treated adjuvantly and those with
neuroendocrine tumours, the median survival for the 27
patients with advanced adenocarcinomas was 9 months, with
33% of patients surviving > 18 months. Survival was longer
for those with colorectal primaries (median survival 10.5
months) than other adenocarcinomas (median surivival 6.5
months). For comparison, in our previous study of FUra/LV
without IFN-a (Johnson et al., 1991), median survival was 7
months for colorectal cancer patients and 6 months for those
with other adenocarcinomas.
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son et al., 1991).
The demonstration of cytotoxic synergy in preclinical models
is no guarantee of a beneficial interaction in the clinic.
Several issues are difficult or impossible to assess in the
laboratory: exposure to one or both agents may be restricted
in solid tumours; unforeseen interactions may occur in the
complex biological milieu; the independent side-effects of the
two agents may add up to unacceptable overall toxicity.
Most importantly of all, the cytotoxic interaction observed in
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Table n Anti-tumour responses
IF.V-a dose level PR MR SD PD NA
1.5 1 1 2
3.0 1 3
4.5 1 1 2
6.0 6 (1') 2 3b
9.0 3 1 4
Total 12 2 3 1 1 3
'One patient moved away with SD after six cycles to continue
treatment elsewhere, but was never adequately reassessed. Died at 33
weeks. 'Two treated adjuvantly; one treated with unmeasurable
disease.
tumour cell lines may turn out to be just as active against
key host target tissues. such as haematological or mucosal
progenitors. IFN cytotoxic drug interactions present partic-
ular difficulties to investigators since the species restriction of
interferons confounds the assessment of therapeutic index in
animal models.
Clinical studies of the FUra'LV IFN-x combination must
therefore address a number of separate questions:
(a) Does IFN-a potentiate the anti-tumour activity of FUra
(or FUra'LV)?
(b) Does IFN-a also potentiate toxicity towards those host
tissues that limit the FUra dose?
(c) If the answers to (a) and (b) are both 'yes'. what is the
ratio of these effects - i.e. does IFN-a improve the
therapeutic index?
(d) Does IFN-x introduce additional, independent toxicity
which limits the clinical usefulness of the combination
(for example by offsetting the palliative benefit in
patients with advanced disease)?
This study has established that IFN-m2a. at a dose of
6 MU on alternate days. may be added to the 'de Gramont'
regimen of FUra and LV. IFN-a carries well-known and
variable subjective side-effects such as lethargy and malaise.
so that even at this recommended dose a proportion of
patients will require dose reduction if quality of life is to be
preserved. However, no correlation was found between IFN-a
dose and FUra-associated toxicities in this phase I study. and
only minor differences were found with historical toxicity
data for FUra LV alone. Thus we have found no evidence
that IFN-a, at this dose, increases the toxicity of FUra and
LV to those tissues that limit their dose.
A non-randomised study is not able to determine whether
IFN-a has increased the anti-tumour effect; however, retro-
spective comparison may be made with a similar population
of patients, treated with the same regimen of FUra LV (with-
out IFN-x) in our hospital, immediately prior to initiating
this study. In that study, objective responses occurred in
10 33 assessable patients with colorectal cancer and 5 17 of
the other adenocarcinoma patients (Johnson et al.. 1991). By
comparison, in the current study, combining all IFN-x dose
levels, responses occurred in 7 14 patients with colorectal
cancer and 4 11 other adenocarcinoma patients.
Another important issue in the clinic is pharmacokinetic
interaction: some studies (but not all) have suggested that. in
certain schedules. IFN-a reduces the plasma clearance of
FUra (reviewed in Seymour et al., 1994). This has led to the
suggestion that IFN-x may be acting, at least in part, as a
toxic and expensive alternative to increasing the dose of
FUra. However, the pharmacokinetic interaction is well
established only for doses of IFN-a around 10 MU per day
or higher (Grem et al., 1991). In a separate report from this
unit, no effect was found of IFN-a at 6 MU alternate days
upon either the bolus or the infusional phases of FUra
kinetics in the regimen used in this study (Seymour et al..
1994).
Our results are consistent with those of other phase I trials
of the combination. Grem et al. (1991) and Bukowski et al.
(1992) both added daily IFN-a2a to a 5 day bolus FUra LV
regimen. The MTD of IFN-a was determined as 5 MU m-
day-' and 4 MU m~- day-' respectively. This regimen has
subsequently shown promising activity in a phase II trial
(Grem et al., 1993). Punt et al. (1992) added alternate-day
IFN-a2b to a 48 h infusional FUra regimen. In all of these
studies, enhancement of FUra-associated toxicity (mucositis.
diarrhoea, myelosuppression) was seen only at total IFN-a
doses above 8-10 MU per day, the same dose range appar-
ently required for pharmacokinetic interaction. In another
trial, no enhancement of FUra 'LV side-effects was detected
with the addition of IFN-m2a even at 18 MU per day (Sin-
nige et al.. 1993).
Improvements in FUra therapy. even if modest. are of
great clinical importance thanks to the unique status of this
drug in the treatment of common cancers. IFN-a has shown
clear evidence of interaction with FUra/LV in the laboratory:
this study has shown that it may be added to FUra LV in the
clinic with little or no potentiation of FUra-associated tox-
icity. but with the addition of the usual IFN-a toxicities.
Promising activity has been observed, in terms of objective
tumour response rate and survival.
However, the results of this and the other phase I and II
studies mentioned do not suggest that IFN-a has a very
dramatic effect, and it is most unlikely that further non-
randomised studies will answer the question of whether IFN-
a's activity translates from the laboratory to the clinic. A
prospective randomised trial is required both to determine
whether IFN-a increases the anti-tumour efficacy of FUra
LV and to quantify the effects of IFN-x on the quality of life
of this patient population. To this end, a multicentre ran-
domised phase II study has just been completed in the UK,
in 260 patients with advanced colorectal cancer (Medical
Research Council trial CR04). The control arm is the FUra
LV regimen described in this paper (at 400 mg m2 FUra,
bolus+ infusion day I + 2), with patients randomised to
receive, in addition, IFN-a2a 6 MU on alternate days
throughout. Careful assessment is being made of anti-tumour
activity in terms of objective response and survival, but also
of treatment-associated toxicity and overall palliative benefit,
using patient-assessed quality of life. This trial will be crucial
in determining whether IFN-x has anything useful to add to
the clinical activity of FUra LV in patients with colorectal
cancer.
References
ACCMP (ADVANCED COLORECTAL CANCER META-ANALYSIS
PROJECT) (1992). Modulation of fluorouracil by leucovorin in
patients with advanced colorectal cancer: evidence in terms of
response rate. J. Clin. Oncol.. 10, 896-903.
BUKOWSKI. R.M.. INOSHITA. G.. YALAVARTHI. P.. MURTHY. S..
GIBSON. V.. BUDD. BT.. SERGI. J1S.. BAUER. L. & PRESTI-
FILIPPO. J. (1992). A phase I trial of 5-fluorouracil. folinic acid.
and alpha-2a-interferon in patients with metastatic colorectal car-
cinoma. Cancer. 69, 889-892.
CHU. E.. ZINN. S.. BOARMAN. D. & ALLEGRA. CJ. (1990). Interac-
tion of y interferon and 5-fluorouracil in H630 human colon
carcinoma cell line. Cancer Res.. 50, 5834-5840.
DE GRAMONT. A.. KRULIK. M.. CADY. J.. LAGADEC. B.. MAISANI.
J.. LOISEAU. J.. GRANGE. J.-D.. GONZALEZ-CANALI. G.. DE-
MUYNCK. B.. LOUVET. C.. SEROKA. J.. DRAY. C. & DEBRAY. J.
(1988). High-dose folinic acid and 5-fluorouracil bolus and con-
tinuous infusion in advanced colorectal cancer. Eur. J. Clin.
Oncol.. 24, 1499-1503.
ELIAS. L. & CRISSMAN. H.A. (1988). Interferon effects upon the
adenocarcinoma 38 and HL-60 cell lines: antiproliferative res-
ponses and synergistic interactions with halogenated pyrimidine
antimetabolites. Cancer Res.. 48, 4868-4873.FUra. INTERFERON m AND LEUCOVORIN - PHASE I AND 11 STUDY 723
ELIAS. L. & SANDOVAL. J.M. (1989). Interferon effects upon
fluorouracil metabolism by HL-60 cells. Biochem. Biophks. Res.
Commun.. 163, 867-874.
GREM. J.L.. MCATEE. N., MURPHY. R.F.. BALIS. F.M.. STEINBERG.
S.U. HAMILTON. J.M.. SORENSEN. M.. SARTOR. O.. KRAMER.
B.S.. GOLDSTEIN. LiJ.. GAY. L.M.. KAUBO. K.M.. GOLDSPIEL. B.
& ALLEGRA. CJ. (1991). A pilot study of interferon c2a in
combination with fluorouracil plus high-dose leucovorin in
metastatic gastrointestinal carcinoma. J. Clin. Oncol.. 9,
1811- 1820.
GREM. J.L.. JORDAN. E.. ROBSON. M.E.. HAMILTON. J.M.. STEIN-
BERG. S.M.. ARBUCK. SG.. BEVERIDGE. RA.. KALES. A.N..
MILLER. I.A.. WEISS. R.B.. MCATEE. N.. CHEN. A.. GOLDSPIEL.
B.. SOVER. E. & ALLEGRA. C.J. (1993). Phase II study of
fluorourcil. leucovorin and interferon-m2a in metastatic colorectal
carcinoma. J. Clin. Oncol.. 11, 1737-1745.
HOUGHTON. J.A.. ADKINS. D.A.. RAHMAN. A. & HOUGHTON. PJ.
(1991). Interaction between 5-fluorouracil. [6RS] leucovorin. and
recombinant human interferon-m2a in cultured colon adenocar-
cinoma cells. Cancer Commun.. 3, 225-231.
HOUGHTON. J.A.. MORTON. C.L.. ADKINS. D.A. & RAHMAN. A.
(1993). Locus of the interaction among 5-fluorouracil. leucovorin.
and interferon-a2a in colon carcinoma cells. Cancer Res.. 53,
4243-4250.
JOHNSON. P.M.W.. THOMPSON. P.LI. SEYMOUR. M.T.. DEASY. N.P..
THURAISINGHAM. R.C.. SLEVIN. M.L. & WRIGLEY. P.F.M.
(1991). A less toxic regimen of 5-fluorouracil and high dose
folinic acid for gastrointestinal adenocarcinomas. Br. J. Cancer.
64, 603-605.
KEMENY. N.. YOUN-ES. A.. SEITER. K.. KELSEN. D.. SAMMARCO. P..
ADAMS. L.. DERBY. S.. MURRAY. P. & HOUSTON. C. (1990).
Interferon-m2a and 5-fluorouracil for advanced colorectal car-
cinoma. Assessment of activity and toxicity. Cancer. 66,
2470-2475.
LOKICH. J.J.. AHLGREN. J.D.. GULLO. JJ.. PHILIPS. J.A. & FRYER.
J.G. (1989). A prospective randomized comparison of continuous
infusion fluorouracil with a conventional bolus schedule in meta-
static colorectal carcinoma: a Mid-Atlantic Oncology Program
studv. J. Clin. Oncol.. 7, 425-432.
NEEFE. J.R. & GLASS. J. (1991). Abrogation of interferon-induced
resistance to interferon-activated major histocompatibility com-
plex-unrestricted killers by treatment of a melanoma cell line with
5-fluorouracil. Cancer Res.. 51, 3159-3163.
PETRELLI. N.. DOUGLASS. H.O.. HERRERA. L.. RUSSELL. D.. STAB-
LEIN. D.M.. BRUKNER. H.W.. MAYER. RJ.. SCHINELLA. R..
GREEN. M.D.. MUGGIA. F.M.. MEGIBOW. A.. GREENWALD. E.S..
BUKOWSKI. R.M.. HARRIS. J., LEVIN. B.. GAYNOR. E.. LOUTFI.
A.. KALSER. M.H.. BARKIN. J.S.. BEN-EDETTO. P.. WOOLEY. P.V..
NAU'TA. R.. WEAVER. D.W. & LEICHMAN. L.P. (1989). The
modulation of fluorouracil with leucovorin in metastatic colorec-
tal carcinoma: a prospective randomized phase III trial. J. Clin.
Oncol.. 7, 1419-1426.
POON. M.A.. O'CONNELL. MJ.. WIEAND. H.S.. KROOK. J.E.. GERS-
TNER. J.B.. TSCHETTER. L.K.. LEVITT. R.. KARDINAL. C.G. &
MAILLIARD. J.A. (1991). Biochemical modulation of fluorouracil
with leucovorin: confirmatory evidence of improved therapeutic
efficacy in advanced colorectal cancer. J. Clin. Oncol.. 9,
1967-1972.
PUN'T. C.J.A.. DE MULDER. P.H.M.. BURGHOU-TS. J.T.M. & WAGE-
NERW D.J.T. (1992). Alpha-interferon in combination with 5-
fluorouracil and leucovorin in metastatic colorectal cancer: a
phase I study. Cancer Chemother. Pharmacol.. 29, 326-328.
SCHWARTZ, E.L.. HOFFMAN. M.. O'CONNOR. CJ. & WADLER_ S.
(1992). Stimulation of 5-fluorouracil metabolic activation by
interferon-c in human colon carcinoma cells. Biochem. Biophks.
Res. Commun.. 182, 1232-1239.
SEYMOUR. M.T.. DOBSON. N.. CLEMENS. MJ. & SLEVIN. M.L.
(1992a). 5-Fluorouracil interferon-a synergy: is regulation of ex-
pression of thymidylate synthase the key? Proc. .4nnu. Meet. Am.
Assoc. Cancer Res.. 33, 545.
SEYMOUR. M.T.. MCSHEEHY. P.MJ.. RODRIGUES. L. & GRIFFITHS.
J.R. (1992b). Modulation by interferon-a of 5-fluorouracil kinetics
in human colon tumour HT29 grown in nude mice: a '9F-MRS
study. Soc. Magnetic Resonance Mfed.. 11, 3514.
SEYMOUR. M.T.. PATEL. N.. JOHNSTON. A.. JOEL. S.P. & SLEVIN.
M.L. (1994). Lack of effect of interferon-m2a upon fluorouracil
pharmacokinetics. Br. J. Cancer. 70, 000-000.
SHAH. A.. MACDONALD. W.. GOLDIE. J.. GUDAUSKAS. G. & BRISE-
BOIS. B. (1985). 5-Fluorouracil infusion in advanced colorectal
cancer: a comparison of three dose schedules. Cancer Treat. Rep..
69, 739-742.
SIN-NIGE. H.A.M.. BUTER. J.. DE VRIES. E.G.E.. UGES. D.R.A..
ROENHORST. H.W.. VERSCHUEREN. R.C.J.. SLEUFER. D.T..
WILLEMSE. P.H.B. & MULDER. N.H. (1993). Phase I-II study of
the addition of .2a interferon to 5-fluorouracil leucovorin. Phar-
macokinetic interaction of x2a interferon and leucovorin. Eur. J.
Cancer. 29A, 1715-1720.
WADLER. S. & SCHWARTZ. E.L. (1990). Antineoplastic activity of the
combination of interferon and cytotoxic agents against experi-
mental and human malignancies: a review. Cancer Res.. 50,
3473-3486.
WEINERMAN. B.. SHAH. A.. FIELDS. A.. CRIPPS. I.C.. WILSON. K..
MCCORMICK. R.. TEMPLE. W.. MAROUN'. J.. BOGUES. W. &
PATER. J. (1992). Systemic infusion versus bolus chemotherapy
with 5-fluorouracil in measurable metastatic colorectal cancer.
Am. J. Clin. Oncol.. 15, 518-523.
WHO (WORLD HEALTH ORGANIZATION) (1979). Handbook for
Reporting Results of Cancer Treatment. World Health Organis-
ation Offset Publication No. 48. WHO: Geneva.
YEE. L.K.. ALLEGRA. C.J.. STEINBERG. S.M. & GREM. J.L. (1992).
Decreased catabolism of fluorouracil in peripheral blood mono-
nuclear cells during combination chemotherapy with fluorouracil.
leucovorin and interferon-m2a. J. Natl Cancer Inst.. 84, 1820-
1825.